Indeed, in CRC, Liao et al. [57] and others showed that PRMT1-mediated EGFR methylation increases tumorigenesis in an orthotopic CRC mouse model and mediates resistance to cetuximab treatment in triple-negative breast cancer cells and head and neck cancer, suggesting that PRMT1 is highly related to EGFR functionality [10, 57, 71–73]. This evidence concerns the gene PRMT1 and colorectal carcinoma.